Barclays’s Revelation Biosciences REVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-24
Closed -$173 – 5666
2026
Q2
$173 Buy
+24
New +$182 ﹤0.01% 5130

Other funds holding REVB

Barclays's REVB Position: Q3 2026 in Review

Barclays sold out of Revelation Biosciences (REVB) in Q3 2026, closing a stake of 24 shares — an estimated $173 sold.

Barclays first reported a position in REVB in Q2 2026 and held it in 1 quarter. The position peaked at $173 in Q2 2026. 12 funds tracked by Wall St. Rank hold REVB as of Q3 2026.

  • Barclays reported no remaining Revelation Biosciences position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 24 Revelation Biosciences shares in Q3 2026, an estimated $173.
  • Barclays first reported a position in Revelation Biosciences in Q2 2026 and held it in 1 quarter.
  • Barclays's Revelation Biosciences position peaked at $173 in Q2 2026.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.